Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Provectus Biopharmaceuticals Inc's Business Segments
Provectus Biopharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Clinical Stage Biotechnology Segment
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Clinical Stage Biotechnology Segment0%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Clinical Stage Biotechnology Segment | $ 0 | - |
Description of Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals Inc is a biotechnology company that specializes in the development of drugs for the treatment of cancer and dermatologic disorders. The company is headquartered in Knoxville, Tennessee, and was founded in 2002.
Provectus is focused on the development of novel therapeutics that utilize its proprietary technology platform, known as PV-10. PV-10 is an injectable formulation of rose bengal disodium, a dye that has been used for decades in various medical applications.
The company's lead product candidate is PV-10, which is currently being evaluated in various clinical trials for the treatment of several types of cancer, including melanoma, breast cancer, and liver cancer. PV-10 works by selectively targeting and destroying tumor cells when injected directly into the tumor. The treatment is minimally invasive and has shown promising results in early clinical trials.
In addition to its work in oncology, Provectus is also developing a topical formulation of rose bengal called PH-10 for the treatment of dermatologic disorders, such as psoriasis and atopic dermatitis. PH-10 works by modulating the immune response in the skin to reduce inflammation and improve symptomatology.
Provectus has a robust intellectual property portfolio, with multiple patents and patent applications covering its PV-10 and PH-10 technologies. These patents provide the company with exclusive rights to develop and commercialize its product candidates in specific regions and indications.
The company has a strong management team with extensive experience in the biopharmaceutical industry. They have successfully guided Provectus through various stages of drug development and clinical trials, and have established strategic partnerships and collaborations with other companies and research institutions.
Provectus has also received funding from government agencies, including the National Institutes of Health (NIH), to support its research and development efforts. This funding has helped accelerate the advancement of its product candidates and expand its pipeline of potential treatments.
The company's long-term vision is to become a leader in the development of innovative therapies for cancer and dermatologic disorders. They are committed to advancing their product candidates through clinical trials, obtaining regulatory approvals, and ultimately bringing their treatments to market to improve patient outcomes.
Overall, Provectus Biopharmaceuticals Inc is a biotechnology company that is at the forefront of developing novel therapies for cancer and dermatologic disorders. With a strong technology platform, promising clinical pipeline, and experienced management team, the company is well positioned to make a significant impact in the field of biopharmaceuticals.
Provectus is focused on the development of novel therapeutics that utilize its proprietary technology platform, known as PV-10. PV-10 is an injectable formulation of rose bengal disodium, a dye that has been used for decades in various medical applications.
The company's lead product candidate is PV-10, which is currently being evaluated in various clinical trials for the treatment of several types of cancer, including melanoma, breast cancer, and liver cancer. PV-10 works by selectively targeting and destroying tumor cells when injected directly into the tumor. The treatment is minimally invasive and has shown promising results in early clinical trials.
In addition to its work in oncology, Provectus is also developing a topical formulation of rose bengal called PH-10 for the treatment of dermatologic disorders, such as psoriasis and atopic dermatitis. PH-10 works by modulating the immune response in the skin to reduce inflammation and improve symptomatology.
Provectus has a robust intellectual property portfolio, with multiple patents and patent applications covering its PV-10 and PH-10 technologies. These patents provide the company with exclusive rights to develop and commercialize its product candidates in specific regions and indications.
The company has a strong management team with extensive experience in the biopharmaceutical industry. They have successfully guided Provectus through various stages of drug development and clinical trials, and have established strategic partnerships and collaborations with other companies and research institutions.
Provectus has also received funding from government agencies, including the National Institutes of Health (NIH), to support its research and development efforts. This funding has helped accelerate the advancement of its product candidates and expand its pipeline of potential treatments.
The company's long-term vision is to become a leader in the development of innovative therapies for cancer and dermatologic disorders. They are committed to advancing their product candidates through clinical trials, obtaining regulatory approvals, and ultimately bringing their treatments to market to improve patient outcomes.
Overall, Provectus Biopharmaceuticals Inc is a biotechnology company that is at the forefront of developing novel therapies for cancer and dermatologic disorders. With a strong technology platform, promising clinical pipeline, and experienced management team, the company is well positioned to make a significant impact in the field of biopharmaceuticals.
Provectus Biopharmaceuticals Inc. is a biotechnology company that primarily focuses on the development and commercialization of innovative therapies for oncology and dermatology. The companys key segments, products, and services can be extensively described as follows:
Segments
1. Oncology Segment
This segment centers around the development of therapies aimed at treating various types of cancer. Provectus focuses on harnessing the advanced properties of its formulations to target malignant tumors while minimizing impact on healthy tissues.
Dermatology Segment
The dermatology segment provides treatments tailored to skin conditions, including some that have the potential to be used in aesthetic applications. The company develops therapies that leverage unique formulations aimed at improving skin health and addressing dermatological diseases.
Products and Services
1. PV-10 (Rose Bengal)
PV-10 is Provectuss lead product candidate, primarily under investigation for various solid tumors, including melanoma. Its a proprietary formulation of rose bengal, a synthetic dye, that is designed for direct injection into tumors. The mechanism involves a dual action of inducing tumor cell apoptosis and stimulating an immune response. Notably, PV-10 is investigated for the treatment of:
- Melanoma: PV-10 has undergone several clinical trials to evaluate its efficacy and safety for patients with cutaneous and subcutaneous metastatic melanoma.
- Other Solid Tumors: Research is also exploring PV-10s applicability in other cancers such as breast cancer, liver cancer, and lung cancer, among others.
PH-10
This product is a topical formulation of a derivative of rose bengal designed for the treatment of dermatological conditions such as psoriasis and atopic dermatitis. PH-10 serves as a localized therapy aimed at reducing inflammation and skin lesions. Its development focuses on leveraging the anti-inflammatory and immune-modulating properties of the active ingredient.
Other Therapeutic Candidates
In addition to PV-10 and PH-10, Provectus may have a pipeline of other therapeutic candidates in preclinical or clinical stages. These candidates are often focused on utilizing similar mechanisms of action as their leading products, including investigational therapies for various cancers and skin disorders.
Services
1. Clinical Trials and Research
Provectus engages in conducting clinical trials to gather critical data on the safety and efficacy of its product candidates. This involves:
- Phase I Trials: Assessing safety, dosage ranges, and side effects in a small group of participants.
- Phase II Trials: Focusing on efficacy and further evaluating safety in a larger participant pool.
- Phase III Trials: Large-scale testing to confirm effectiveness, monitor side effects, and compare to standard or placebo treatments.
Regulatory Affairs
Provectus is committed to navigating the regulatory landscape to achieve necessary approvals from entities such as the U.S. Food and Drug Administration (FDA) and other global regulatory bodies. This service includes:
- Preparing and submitting Investigational New Drug (IND) applications.
- Working through the process of New Drug Applications (NDA) or Biologics License Applications (BLA) for approved therapies.
Collaborative Research
Provectus may engage in partnerships and collaborations with academic institutions, research organizations, and pharmaceutical companies to advance its research and development efforts. These collaborations often focus on expanding the understanding of its therapies, enhancing scientific research, or sharing resources.
Education and Awareness Initiatives
To support its product candidates and therapeutic areas, Provectus likely participates in educational initiatives aimed at healthcare professionals and patients to raise awareness about its therapies, treatment options for various cancers and skin conditions, and ongoing clinical trials.
Conclusion
Provectus Biopharmaceuticals Inc. operates in the specialized intersections of biotechnology, oncology, and dermatology, focusing on novel therapies that harness the potential of rose bengal derivatives. Its products and services reflect a commitment to innovation in treating malignancies and inflammation-related dermatological conditions while navigating the regulatory pathways of drug development and fostering collaborative research efforts for the benefit of patients and the scientific community.
Segments
1. Oncology Segment
This segment centers around the development of therapies aimed at treating various types of cancer. Provectus focuses on harnessing the advanced properties of its formulations to target malignant tumors while minimizing impact on healthy tissues.
Dermatology Segment
The dermatology segment provides treatments tailored to skin conditions, including some that have the potential to be used in aesthetic applications. The company develops therapies that leverage unique formulations aimed at improving skin health and addressing dermatological diseases.
Products and Services
1. PV-10 (Rose Bengal)
PV-10 is Provectuss lead product candidate, primarily under investigation for various solid tumors, including melanoma. Its a proprietary formulation of rose bengal, a synthetic dye, that is designed for direct injection into tumors. The mechanism involves a dual action of inducing tumor cell apoptosis and stimulating an immune response. Notably, PV-10 is investigated for the treatment of:
- Melanoma: PV-10 has undergone several clinical trials to evaluate its efficacy and safety for patients with cutaneous and subcutaneous metastatic melanoma.
- Other Solid Tumors: Research is also exploring PV-10s applicability in other cancers such as breast cancer, liver cancer, and lung cancer, among others.
PH-10
This product is a topical formulation of a derivative of rose bengal designed for the treatment of dermatological conditions such as psoriasis and atopic dermatitis. PH-10 serves as a localized therapy aimed at reducing inflammation and skin lesions. Its development focuses on leveraging the anti-inflammatory and immune-modulating properties of the active ingredient.
Other Therapeutic Candidates
In addition to PV-10 and PH-10, Provectus may have a pipeline of other therapeutic candidates in preclinical or clinical stages. These candidates are often focused on utilizing similar mechanisms of action as their leading products, including investigational therapies for various cancers and skin disorders.
Services
1. Clinical Trials and Research
Provectus engages in conducting clinical trials to gather critical data on the safety and efficacy of its product candidates. This involves:
- Phase I Trials: Assessing safety, dosage ranges, and side effects in a small group of participants.
- Phase II Trials: Focusing on efficacy and further evaluating safety in a larger participant pool.
- Phase III Trials: Large-scale testing to confirm effectiveness, monitor side effects, and compare to standard or placebo treatments.
Regulatory Affairs
Provectus is committed to navigating the regulatory landscape to achieve necessary approvals from entities such as the U.S. Food and Drug Administration (FDA) and other global regulatory bodies. This service includes:
- Preparing and submitting Investigational New Drug (IND) applications.
- Working through the process of New Drug Applications (NDA) or Biologics License Applications (BLA) for approved therapies.
Collaborative Research
Provectus may engage in partnerships and collaborations with academic institutions, research organizations, and pharmaceutical companies to advance its research and development efforts. These collaborations often focus on expanding the understanding of its therapies, enhancing scientific research, or sharing resources.
Education and Awareness Initiatives
To support its product candidates and therapeutic areas, Provectus likely participates in educational initiatives aimed at healthcare professionals and patients to raise awareness about its therapies, treatment options for various cancers and skin conditions, and ongoing clinical trials.
Conclusion
Provectus Biopharmaceuticals Inc. operates in the specialized intersections of biotechnology, oncology, and dermatology, focusing on novel therapies that harness the potential of rose bengal derivatives. Its products and services reflect a commitment to innovation in treating malignancies and inflammation-related dermatological conditions while navigating the regulatory pathways of drug development and fostering collaborative research efforts for the benefit of patients and the scientific community.